Linkedin
RLS logo_header
Linkedin

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

“We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.”

Read the full story on "Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics"

Share:

More News

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Gen T-cell Engaging Multispecific Antibodies

“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies

Final Patient Dosed in Ph 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most

FAILED TRIAL: Ph 3 TRIDENT trial of TTFields did not meet primary endpoint of significant OS increase in GBM patients when used early

“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT

FDA Fast Track Designation for Givastomig in 1L HER2-Neg Metastatic Gastric Cancer

“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a